11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
40 citations
,
January 2017 in “Intestinal Research” Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
1 citations
,
August 2024 in “British Journal of Dermatology” Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
January 2022 in “Asian journal of Current Research in Clinical Cancer” Some dibenzo compounds might help treat cancer with fewer side effects.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
13 citations
,
January 2021 in “The American journal of gastroenterology” Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.
1 citations
,
January 2025 in “Frontiers in Oncology” REV7 is crucial for genome stability and cancer treatment, making it a potential target for therapy.
December 2025 in “Journal of Human Immunity” JAK inhibitors may help improve symptoms in adults with APECED.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
June 2015 in “Reactions Weekly” A man developed alopecia areata after starting cancer treatment with vandetanib.
23 citations
,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
Suppressing ODC activity reduces tumor growth in hair follicles.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
May 2025 in “International Journal of Trichology” Baricitinib may effectively treat sudden hair whitening and regrowth in some cases.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
4 citations
,
January 2014 in “The Journal of urology/The journal of urology” Kidney cancer cells without folliculin are more sensitive to radiation due to increased self-eating cell death.
36 citations
,
October 2009 in “Journal of biological chemistry/The Journal of biological chemistry” Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
November 2025 in “Russian Journal of Oncology” Modifying steroidal inhibitors shows promise for developing new cancer treatments.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
1 citations
,
April 2022 in “F1000Research” Most pediatric cancer patients at Muhimbili National Hospital in Tanzania experienced side effects from chemotherapy, with nausea, hair loss, and low white blood cell count being the most common.
March 2005 in “The Nurse Practitioner”
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.